These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24064478)

  • 1. Effect of insulin glargine on endogenous insulin secretion and beta-cell function in Japanese type 2 diabetic patients using oral antidiabetic drugs.
    Ohta A; Kato H; Murayama K; Hashimoto E; Murakami M; Nishine A; Ohshige T; Sada Y; Asai S; Kawata T; Nagai Y; Katabami T; Tanaka Y
    Endocr J; 2014; 61(1):13-8. PubMed ID: 24064478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of sitagliptin on glycemic control and beta cell function in Japanese patients given basal-supported oral therapy for type 2 diabetes.
    Asai S; Ohta A; Kato H; Sada Y; Nagai Y; Kondo A; Sasaoka T; Tanaka Y
    Endocr J; 2014; 61(12):1213-20. PubMed ID: 25231694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adding insulin glargine vs. NPH insulin to metformin results in a more efficient postprandial beta-cell protection in individuals with type 2 diabetes.
    Forst T; Larbig M; Hohberg C; Forst S; Diessel S; Borchert M; Roth W; Pfützner A
    Diabetes Obes Metab; 2010 May; 12(5):437-41. PubMed ID: 20415692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of insulin glargine versus metformin on glycemic variability, microvascular and beta-cell function in early type 2 diabetes.
    Pistrosch F; Köhler C; Schaper F; Landgraf W; Forst T; Hanefeld M
    Acta Diabetol; 2013 Aug; 50(4):587-95. PubMed ID: 23430192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of glargine versus glimepiride on pancreatic β-cell function in patients with type 2 diabetes uncontrolled on metformin monotherapy: open-label, randomized, controlled study.
    Moon JS; Ha KS; Yoon JS; Lee HW; Lee HC; Won KC;
    Acta Diabetol; 2014 Apr; 51(2):277-85. PubMed ID: 24445656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P; Cooper J; Bregnhøj J; Pedersen CB
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU; Plewe G; Busch K
    J Am Geriatr Soc; 2007 Feb; 55(2):182-8. PubMed ID: 17302653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
    Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
    Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
    Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In type 2 diabetes patients, insulin glargine is associated with lower postprandial release of intact proinsulin compared with sulfonylurea treatment.
    Pscherer S; Larbig M; von Stritsky B; Pfützner A; Forst T
    J Diabetes Sci Technol; 2012 May; 6(3):634-40. PubMed ID: 22768894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who switched from premixed insulin to insulin glargine plus oral antidiabetics: a large, prospective, observational study.
    Zhang B; Zhao J; Yang W;
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 27667797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
    Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
    Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-level meta-analysis of efficacy and hypoglycaemia in people with type 2 diabetes initiating insulin glargine 100U/mL or neutral protamine Hagedorn insulin analysed according to concomitant oral antidiabetes therapy.
    Owens DR; Traylor L; Mullins P; Landgraf W
    Diabetes Res Clin Pract; 2017 Feb; 124():57-65. PubMed ID: 28092788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with type 2 diabetes previously on long-term conventional insulin therapy: the Switch pilot study.
    Schiel R; Müller UA
    Exp Clin Endocrinol Diabetes; 2007 Nov; 115(10):627-33. PubMed ID: 18058596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosing of insulin glargine to achieve the treatment target in Japanese type 2 diabetes on a basal supported oral therapy regimen in real life: ALOHA study subanalysis.
    Odawara M; Ohtani T; Kadowaki T
    Diabetes Technol Ther; 2012 Jul; 14(7):635-43. PubMed ID: 22524524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.
    Rosenstock J; Cheng A; Ritzel R; Bosnyak Z; Devisme C; Cali AMG; Sieber J; Stella P; Wang X; Frías JP; Roussel R; Bolli GB
    Diabetes Care; 2018 Oct; 41(10):2147-2154. PubMed ID: 30104294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L; Kesavadev J; Demissie M; Nazeri A; Hollander P
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of basal insulin glargine 12 and 24 weeks after initiation in persons with type 2 diabetes: a pooled analysis of data from treatment arms of 15 treat-to-target randomised controlled trials.
    Owens DR; Traylor L; Dain MP; Landgraf W
    Diabetes Res Clin Pract; 2014 Nov; 106(2):264-74. PubMed ID: 25195151
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of baseline glycemia on outcomes with insulin glargine use in patients uncontrolled on oral agents.
    Banerji MA; Baron MA; Gao L; Blonde L
    Postgrad Med; 2014 May; 126(3):111-25. PubMed ID: 24918797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
    Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.